期刊文献+

左乙拉西坦添加治疗儿童难治性癫痫的临床疗效及安全性 被引量:12

原文传递
导出
摘要 目的研究左乙拉西坦(LEV)添加治疗儿童难治性癫痫的疗效及安全性。方法对65名难治性癫痫儿童进行LEV添加治疗,观察治疗前及治疗后3、6、12个月患儿的临床发作、脑电图改变及不良反应等。结果治疗后3、6、12个月的完全控制率分别为6.9%、10.3%、3.4%,有效率分别为44.8%、58.6%、39.6%;治疗后6个月的EEG改善率为65.5%,其与临床疗效存在正相关(r=0.436,P=0.001);LEV 1年保留率89%,3%的难治性癫痫儿童出现不良反应,主要表现为烦躁、精神行为异常等。结论 LEV添加治疗儿童难治性癫痫起效快,疗效确切,不良反应少。
出处 《中华临床医师杂志(电子版)》 CAS 2014年第7期138-140,共3页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献13

  • 1Wirrell EC, Grossardt BR, Wong-Kisiel LC, et al. Incidence andclassification of new-onset epilepsy and epilepsy syndromes inchildren in Olmsted County, Minnesota from 1980 to 2004: apopulation-based study [J]. Epilepsy Res, 2011,95(1/2): 110-118.
  • 2Sinha S, Siddiqui KA. Definition of intractable epilepsy[J].Neurosciences(Riyadh), 2011,16(1): 3-9.
  • 3洪桢,洪震,周东.耐药性癫痫的定义:国际抗癫痫联盟治疗策略委员会专项工作组统一提案[J].中华神经科杂志,2010,43(7):487-492. 被引量:21
  • 4胡雁,廖建湘,陈黎,黄铁栓,李冰.左乙拉西坦添加治疗4岁以下儿童难治性癫癎的疗效和安全性研究[J].中国当代儿科杂志,2010,12(4):256-258. 被引量:21
  • 5张轶群,李吉,胡玉,田韵,高常青.抗癫痫药物左乙拉西坦[J].中国神经免疫学和神经病学杂志,2010,17(2):145-147. 被引量:10
  • 6Terada K, Inoue Y. Clinical application of newer anti-epilepticdrugs [J]. Rinsho Shinkeigaku, 2012,52(11): 1088-1090.
  • 7Kaminski RM, Gillard M, Klitgaard H. Targeting SV2A forDiscovery of Antiepileptic Drugs[M]//Noebels JL, Avoli M,Rogawski MA, et al. SourceJasper's Basic Mechanisms of theEpilepsies [Internet]. 4th ed. Bethesda (MD): National Center forBiotechnology Information (US), 2012.
  • 8Talos DM, Chang M, Kosaras B,et al. Antiepileptic effects oflevetiracetam in a rodent neonatal seizure model[J]. Pediatr Res,2013,73(1): 24-30.
  • 9赵红艳,黄希顺,张存玲.左乙拉西坦添加治疗难治性癫痫的临床疗效[J].中国实用医刊,2009,36(21):48-49. 被引量:6
  • 10Kanemura H, Sano F, Tando T, et al. Efficacy and safety of add-onlevetiracetam in refractory childhood epilepsy[J]. Brain Dev, 2013,35(5): 386-391.

二级参考文献58

  • 1吴洵昳,洪震,吴逊,吴立文,赵忠新,王学峰,周东,吕传真.多中心双盲、随机、安慰剂对照评价左乙拉西坦添加治疗难治性部分性癫癎发作的疗效及安全性[J].中华神经科杂志,2007,40(3):149-153. 被引量:44
  • 2French J. Use of levetiracetam in special populations[J]. Epilepsia, 2001,42:40-43.
  • 3Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives[J]. Neurology, 2006,67 : S56-S58.
  • 4Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: A pharmacodynamic interaction[J].Epilepsy Res,2002,48:217-219.
  • 5Kelly K, Stephen LJ, Brodie MJ. Levetiracetam for people with mental retardation and refractory epilepsy[J]. Epilepsy Behav, 2004,5 : 878-883.
  • 6Privitera M. Efficacy of levetiracetam: A review of three pivotal clinical trials[J].Epilepsia,2001,42 : 31-35.
  • 7Leppik IE, Biton V, Sander JW, et al. Levetiracetam and par tial seizure subtypes: Pooled data from three randomized, pla eebo-eontrolled trials[J].Epilepsia, 2003,44 : 1585-1587.
  • 8Morrell MJ, Leppik I, French J, et al. The KEEPER trial: Levetiracetam adjunctive treatment of partial-onset seizures in an open-label community based study[J]. Epilepsy Res,2003, 54:153-161.
  • 9Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy[J].Neurology, 2007, 68(6):402-408.
  • 10Verdru P, Wajgt A, Schi,emann Delgado J, et al. Efficacy and safety of levetiracetam 3000 mg/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalized ep ilepsy with myoclonic seizures[J]. Epilepsia, 2005,46:56.

共引文献54

同被引文献282

引证文献12

二级引证文献106

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部